Education
About Us
Working with TipRanks
Follow Us
Valerio Therapeutics (FR:ALVIO)
:ALVIO
Total Valuation
Valerio Therapeutics has a market cap or net worth of €10.17M. The enterprise value is ―.
Market Cap€10.17M
Enterprise Value―
Share Statistics
Valerio Therapeutics has 154,364,270 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding154,364,270
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Valerio Therapeutics’s return on equity (ROE) is -1.37 and return on invested capital (ROIC) is -78.33%.
Return on Equity (ROE)-1.37
Return on Assets (ROA)-0.58
Return on Invested Capital (ROIC)-78.33%
Return on Capital Employed (ROCE)-0.84
Revenue Per Employee47.37K
Profits Per Employee-535.37K
Employee Count38
Asset Turnover0.05
Inventory Turnover88.83
Valuation Ratios
The current PE Ratio of Valerio Therapeutics is -1.10. Valerio Therapeutics’s PEG ratio is -0.02.
PE Ratio-1.10
PS Ratio0.00
PB Ratio2.57
Price to Fair Value1.51
Price to FCF-0.59
Price to Operating Cash Flow-0.63
PEG Ratio-0.02
Income Statement
In the last 12 months, Valerio Therapeutics had revenue of 1.80M and earned -20.34M in profits. Earnings per share was -0.15.
Revenue1.80M
Gross Profit1.27M
Operating Income-20.29M
Pretax Income-20.33M
Net Income-20.34M
EBITDA-18.44M
Earnings Per Share (EPS)-0.15
Cash Flow
In the last 12 months, operating cash flow was -16.31M and capital expenditures -126.00K, giving a free cash flow of -16.44M billion.
Operating Cash Flow-16.31M
Free Cash Flow-16.44M
Free Cash Flow per Share-0.11
Dividends & Yields
Valerio Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.06
52-Week Price Change-38.89%
50-Day Moving Average0.06
200-Day Moving Average0.07
Relative Strength Index (RSI)55.99
Average Volume (3m)51.53K
Important Dates
Valerio Therapeutics upcoming earnings date is Jul 24, 2025, TBA Not Confirmed.
Last Earnings DateMar 27, 2025
Next Earnings DateJul 24, 2025
Ex-Dividend Date―
Financial Position
Valerio Therapeutics as a current ratio of 1.17, with Debt / Equity ratio of 328.74%
Current Ratio1.17
Quick Ratio1.17
Debt to Market Cap0.37
Net Debt to EBITDA-0.12
Interest Coverage Ratio-307.39
Taxes
In the past 12 months, Valerio Therapeutics has paid 17.00K in taxes.
Income Tax17.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Valerio Therapeutics EV to EBITDA ratio is -1.33, with an EV/FCF ratio of -1.31.
EV to Sales13.64
EV to EBITDA-1.33
EV to Free Cash Flow-1.31
EV to Operating Cash Flow-1.32
Balance Sheet
Valerio Therapeutics has €4.00M in cash and marketable securities with €13.22M in debt, giving a net cash position of €9.22M billion.
Cash & Marketable Securities€4.00M
Total Debt€13.22M
Net Cash€9.22M
Net Cash Per Share€0.06
Tangible Book Value Per Share-€0.04
Margins
Gross margin is 74.75%, with operating margin of -1127.11%, and net profit margin of -1130.22%.
Gross Margin74.75%
Operating Margin-1127.11%
Pretax Margin-1129.28%
Net Profit Margin-1130.22%
EBITDA Margin-1024.67%
EBIT Margin-1121.50%
Analyst Forecast
The average price target for Valerio Therapeutics is €0.01, which is 11.43% higher than the current price. The consensus rating is Moderate Sell
Price Target€0.01
Price Target Upside-85.71% Downside
Analyst ConsensusModerate Sell
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―